{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-035908","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.215172+00:00","generated_at":"2026-06-19T16:16:29.632845+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vir Bio amends GSK deal: regains full rights to vaccine program, narrows antibody program","bullets":["Amendments remove CoV Vaccine Program from collaboration; Vir retains rights to progress independently.","CoV Antibody Program narrowed to only sotrovimab and VIR-7832; all other antibodies revert to Vir.","Vir pays tiered royalties in low single digits on vaccine sales, low-to-mid single digits on terminated antibodies.","Amendments effective March 31, 2022 (vaccine wind-down) and February 8, 2023 (antibody scope reduction).","GSK retains 50:50 profit share on sotrovimab and VIR-7832 under original DCA terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-035908","json":"https://secwatch.observer/filing/0001193125-23-035908.json","markdown":"https://secwatch.observer/filing/0001193125-23-035908.md","text":"https://secwatch.observer/filing/0001193125-23-035908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000119312523035908/0001193125-23-035908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000119312523035908/d449379d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T16:16:29.632845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6a477c4c4b1f26a5e0fbd53530414ec4acd4f3dd","claim":"Vir Biotechnology, Inc. entered into Amendment No. 2 and Amendment No. 3 to the DCA with GSK (effective 2023-02-08).","evidence_excerpt":"On February 8, 2023, the Company, and GSK entered into Amendment No. 2 and Amendment No. 3 to the DCA (collectively, the “DCA Amendments”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000119312523035908/0001193125-23-035908-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"GSK"},{"label":"Effective","value":"2023-02-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}